Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions

Kyowa Hakko Kirin announced on May 24 that the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza Tablets 2.5 mg and 5 mg (saxagliptin hydrate) for the treatment of type 2 diabetes were included in the NHI price list on the same day...read more